NCT02826434 2025-10-01
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Massachusetts General Hospital
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT03362060 2025-10-01
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04634747 2022-04-20
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
OncoPep, Inc.
Phase 2 Unknown